$0.00
1
3
$0.00
1
3
Trader mode: Actionable analysis for identifying opportunities and edge
COMP360 Psilocybin for Treatment-Resistant Depression If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before X 1, Y then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
AI-generated analysis based on market data. Not financial advice.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
3 markets tracked
No data available
| Market | Platform | Price |
|---|---|---|
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before 2028) | Kalshi | 55% |
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before October 2027) | Kalshi | 43% |
When will the FDA approve COMP360 Psilocybin for Treatment-Resistant Depression? (Before July 2027) | Kalshi | 20% |
No related news found
Add this market to your website
<iframe src="https://predictpedia.com/embed/laxP-U" width="400" height="160" frameborder="0" style="border-radius: 8px; max-width: 100%;" title="When will the FDA approve Compass Pathways' COMP360 Psilocybin?"></iframe>